Roberto Pili

Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer.

Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1.

Is HIF-1 alpha a valid therapeutic target?

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma.

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier.

In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.

A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation.

Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.

Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.

Modeling the cost of management options for stage I nonseminomatous germ cell tumors: a decision tree analysis.

A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target.

Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha.

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.

A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma.

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.

Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.

Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.

Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.

Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.

Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.

The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin.

Platelets take up the monoclonal antibody bevacizumab.

Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration.

Posttranscription regulation of prostate cancer growth.

Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.

Symptoms, supportive care needs, and function in cancer patients: how are they related?

Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.

Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.

Reproducibility of tumor blood flow quantification with 15O-water PET.

Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth.

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.

Targeting tumor angiogenesis with histone deacetylase inhibitors.

VEGF recruits lactosylceramide to induce endothelial cell adhesion molecule expression and angiogenesis in vitro and in vivo.

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Recent investigations of histone deacetylase inhibitors in renal cell carcinoma.

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.

NCCN clinical practice guidelines in oncology: testicular cancer.

NCCN clinical practice guidelines in oncology: kidney cancer.

Concordance of cancer patients' function, symptoms, and supportive care needs.

The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma.

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.

Kidney cancer. Clinical practice guidelines.

Update on novel agents in renal cell carcinoma.

Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model.

Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30.

A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.

Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC.

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.

Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.

Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.

Is this a true renaissance for the treatment of prostate cancer?

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.

Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination.

Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible?

Development of a castrate resistant transplant tumor model of prostate cancer.

Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells.

Provenge: combating prostate cancer with a vengeance?

Kidney cancer.

Role of immunotherapy for renal cell cancer in 2011.

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.

Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.

Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.

Resistance to angiogenesis inhibitors in renal cell carcinoma.

Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule.

Pre-clinical models of renal carcinoma and their utility in drug development.

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.

Testicular cancer.

Mind the gap: potential for rebounds during antiangiogenic treatment breaks.

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.

Contrasting effects of sunitinib within in vivo models of metastasis.

Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells.

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy.

Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer.

Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model.

Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.

Histone modifications: implications in renal cell carcinoma.

Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer.

Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer.

Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer.

Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.

Dietary protein restriction inhibits tumor growth in human xenograft models.

Kidney cancer, version 2.2014.

Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer.